osteoporosis%20in%20women
OSTEOPOROSIS IN WOMEN
Osteoporosis is a progressive, systemic, skeletal disease characterized by decreased bone mass and microarchitectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history of fracture, advanced age, comorbidities, etc) that are present, the greater the risk of fracture.
  1. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001 Jul;44(7):1496-1503. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11465699
  2. Bonura F. Prevention, screening and management of osteoporosis: an overview of the current strategies. Postgrad Med. 2009 Jul;121(4):005-17. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19641263
  3. Brown JP, Fortier M, et al; Osteoporosis Guidelines Committee. Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can. 2006 Feb;28(2)(Suppl 1):S95-S112. http://www.ncbi.nlm.nih.gov/pubmed/?term=16626523. PMID: 16626523
  4. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician. 2003 Apr;67(7):1521-1526. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 12722852
  5. Compston J. Clinical and therapeutic aspects of osteoporosis. Aug 05, 2009. Eur J Radiol. 2009 Sep;71(3):388-391. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19660883
  6. Compston J, Cooper A, Cooper C, et al; National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009 Feb;62(2):105-108. doi: 10.1016/j.maturitas.2008.11.022. PMID: 19135323
  7. Dell RM, Greene D, Anderson D, et al. Osteoporosis disease management: what every orthopaedic surgeon should know. J Bone Joint Surg Am. 2009 Nov;91(Suppl 6):79-86. doi: 10.2106/JBJS.I.00521. PMID: 19884415
  8. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002 Jun;359(9322):2018-2026. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 12076571
  9. Delmas PD, Eastell R, Garnero P, et al; Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. 2000;11(Suppl 6):S2-S17. PMID: 11193237
  10. Hodgson SF, Watts NB, Bilezikian JP, et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003 Nov;9(6):544-564. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 14715483
  11. Kanis JA, Burlet N, Cooper C, et al; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008 Apr;19(4):399-428. http://www.ncbi.nlm.nih.gov/pubmed/?term=18266020. PMID: 18266020
  12. Kanis JA, McCloskey EV, Johansson H, et al. Approaches to the targeting of treatment for osteoporosis. Nat Rev Rheumatol. 2009 Aug;5(8):425-431. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19648943
  13. Lau EM, Sambrook P, Seeman E, et al. Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia. APLAR J Rheumatol. 2006 Apr;9(1):24-36
  14. Levine JP. Pharmacologic and nonpharmacologic management of osteoporosis. Clin Cornerstone. 2006;8(1):40-53. PMID: 17591575
  15. Leweicki EM. Managing osteoporosis: challenges and strategies. Cleve Clin J Med. 2009 Aug;76(8):457-466. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19652039
  16. Leweicki EM. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt). 2009 Oct;18(10):1615-1626. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19857095
  17. Lewiecki EM. Prevention and treatment of postmenopausal osteoporosis. Obstet Gynecol Clin North Am. 2008 Jun;35(2):301-315. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 18486843
  18. Mayes SL. Review of postmenopausal osteoporosis pharmacotherapy. Nutr Clin Pract. 2007 Jun;22(3):276-285. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 17507728
  19. Miller PD. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008 Mar;6(1):012-16. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 18430395
  20. Mazziotti G, Giustina A, Canalis E, et al. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. Arq Bras Endocrinol Metabol. 2007 Nov;51(8):1404-1412. doi: 10.1590/S0004- 27302007000800028. PMID: 18209880
  21. Muenier P, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004 Jan;350(5):459-468. http://www.nejm.org. PMID: 14749454
  22. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May;344(19):1434-1441. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11346808
  23. North American Menopause Society (NAMS). Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010 Mar;17(2):242-255. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 20154637
  24. Poole KES, Compston JE. Osteoporosis and its management. BMJ. 2006 Dec;333(7581):1251-1256. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 17170416
  25. Reginster J, Lecart M, Deroisy R, et al. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Expert Opin Investig Drugs. 2004 Jul;13(7):857-864. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 15212623
  26. Rahmani P, Morin S. Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ. 2009 Nov;181(11):815-820. doi: 10.1503/cmaj.080709. PMID: 19841053
  27. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007 Nov;357(20):2028-2039. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 18003959
  28. Sambrook PN, Seeman E, Phillips SR, et al; Osteoporosis Australia; National Prescribing Service. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust. 2002 Apr;176(Suppl):S1-S16. PMID: 12049064
  29. Seeman E, Eisman J. Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture. Med J Aust. 2004 Mar;180(6):298-303. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 15012571
  30. South-Paul JE. Osteoporosis: part II. Nonpharmacologic and pharmacologic treatment. Am Fam Physician. 2001 Mar;63(6):1121-1128. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11277549
  31. South-Paul JE. Osteoporosis: part I. Evaluation and assessment. Am Fam Physician. 2001 Mar;63(5):897-904, 908. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11261866
  32. Stránský M, Rysavá L. Nutrition as prevention and treatment of osteoporosis. Physiol Res. 2009;58(Suppl 1):S7-S11. http://www.ncbi.nlm.nih.gov/pubmed/?term=19857038. PMID: 19857038
  33. The Hong Kong College of Obstetricians and Gynaecologists. Guidelines for the administration of hormone replacement therapy. Number 2. 2003 Jan. http://hkcog.obg.cuhk.edu.hk.
  34. Woolf AD. An update on glucocorticoid-induced osteoporosis. Curr Opin rheumatol. 2007 Jul;19(4):370-375. PMID: 17551369
  35. North American Menopause Society (NAMS). Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010 Jan;17(1):25-54. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 20061894
  36. National Osteoporosis Foundation. Foundation for Osteoporosis Research and Education: osteoporosis guidelines for the physician. 4th; 2002. http://www.nof.org
  37. Ministry of Health Malaysia, Academy of Medicine Malaysia, Malaysian Osteoporosis Society. Clinical guidelines on management of osteoporosis 2012. http://www.osteoporosis.my. 2012. Accessed 18 Jun 2013.
  38. Malaysian Osteoporosis Society, Academy of Medicine Malaysia. Clinical practice guideline for the management of osteoporosis. http://www.msr.org.my. 2006. Accessed 18 May 2010.
  39. Academy of Medicine Malaysia, Malaysian Osteoporosis Society. Clinical practice guidelines on the management of osteoporosis. http://www.acadmed.org.my. 2000.
  40. Ministry of Health Singapore. Clinical practice guidelines: osteoporosis. MOH (Singapore). http://www.moh.gov.sg. 2008. Accessed 26 May 2010.
  41. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org. 2008.
  42. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://nof.org. 2010.
  43. Schnitzer TJ. Diagnosis and treatment of osteoporosis: current status and expectations for the new millennium. http://www.medscape.com. Dec 2001.
  44. Compston J, Barlow D, et al for the Guidelines Working Group the Royal College of Physicians, The Bone Tooth Society of Great Britain and The National Osteoporosis Society. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. http://www.rcplondon.ac.uk. Dec 2002.
  45. Reginster JY. New agents for the treatment of osteoporosis. http://www.medscape.com. Jan 2003.
  46. Osteoporosis prevention, diagnosis and therapy. National Institute of Health (NIH) consensus statement. Mar 27-29, 2000:1-36. http://www.opd.od.nih.gov.
  47. Finkelstein JS. Overview of osteoporosis in men. UpToDate. http://www.uptodate.com. 2003.
  48. National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture. NICE. http://publications.nice.org.uk. Aug 2012. Accessed 11 Jun 2013.
  49. Rosen HN. Prevention and treatment of glucocorticoid-induced osteoporosis. UpToDate. http://www.uptodate.com. 2002.
  50. Rosen HN, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. UpToDate. http://www.uptodate.com. May 2011. Accessed 22 Sep 2011.
  51. Lie D. Prevention and treatment of osteoporosis in long-term glucocorticoid users. http://www.medscape.com. Aug 2002.
  52. Compston J, Bowring C, Cooper A, et al; National Osteoporosis Guideline Group. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013 Aug;75(4):392-396. doi: 10.1016/j.maturitas.2013.05.013. Accessed 24 Apr 2014. PMID: 23810490
  53. OSHK Task Group for Formulation of 2013 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong, Ip I, Cheung SK, Cheung TC, et al; Osteoporosis Society of Hong Kong. The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J. 2013 Apr;19(Suppl 2):1-40. http://www.hkmj.org. PMID: 23535738
  54. National Institute for Health and Care Excellence; NICE technology appraisal guidance 161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE. https://www.nice.org.uk. 26 Jan 2011. Accessed 10 Jul 2015.
  55. Medicines and Healthcare Products Regulatory Agency. Strontium ranelate: cardiovascular risk. GOV.UK. https://www.gov.uk. 12 Mar 2014. Accessed 10 Jul 2015.
  56. National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. http://www.nof.org. 2014.
  57. Malaysian Osteoporosis Society, Academy of Medicine Malaysia, and Ministry of Health Malaysia. Clinical guidance on management of osteoporosis 2012. Revised 2015. Malaysian Society of Rheumatology (MSR). http://www.msr.my. 2015. Accessed 04 Sep 2015.
  58. Kanis JA, McCloskey EV, Johansson H, et al; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23-57. http://www.ncbi.nlm.nih.gov. Accessed 02 Oct 2014. PMID: 23079689
  59. Li-Yu J, Perez EC, Canete A, et al; Osteoporosis Society of the Philippines Foundation Inc, Philippine Orthopedic Association Clinical Practice Guidelines Task Force Committee on Osteoporosis. Summary of the consensus statements on osteoporosis prevention, diagnosis, and treatment in the Philippines. Journal of ASEAN Federation of Endocrine Societies. http://www.asean-endocrinejournal.org/. 2012.
  60. Adler RA, Fuleihan GE-H, Bauer DC, et al. Managing osteoporosis patients after long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708.
  61. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42. doi: 10.4158/EP161435.GL. Accessed 27 Mar 2017. PMID: 27662240
  62. Facts and statistics. International Osteoporosis Foundation. https://www.iofbonehealth.org/facts-statistics. 2015.
  63. Compston J, Cooper A, Cooper C, et al; National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43. doi: 10.1007/s11657-017-0324-5. PMID: 28425085
  64. National Osteoporosis Guideline Group (NOGG). NOGG 2017: Clinical guideline for the prevention and treatment of osteoporosis. NOGG. https://www.sheffield.ac.uk/NOGG. Mar 2017. Accessed 27 Jul 2017.
  65. Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women; a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017 Jun 6;166(11):818-839. doi: 10.7326/M15-1361. PMID: 28492856
  66. Hauk L. Treatment of low BMD and osteoporosis to prevent fractures: updated guideline from the ACP. Am Fam Physician. 2018 Mar 1;97(5):352-353. https://www.aafp.org. PMID: 29671503
  67. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, et al. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2018 Jun 26;319(24):2521-2531. doi: 10.1001/jama.2018.7498. PMID: 29946735
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Apr 2019
The sodium‐glucose‐cotransporter‐2 inhibitor empagliflozin yields beneficial effects on weight anthropometric parameters and body composition—including weight, body mass index, waist and hip circumference, and total body fat—that are greater than those achieved with metformin in overweight and obese women with polycystic ovary syndrome (PCOS), a study has shown.
Stephen Padilla, 03 Apr 2019
The risk of miscarriage is lowest at age 27 years but increases with older age and by up to four times after three consecutive previous miscarriages, according to a Norway study. This risk is also associated with earlier pregnancy complications, including stillbirth, preterm delivery and gestational diabetes.
Pearl Toh, 08 May 2019
Continuous chemotherapy confers better survival and quality of life than intermittent scheduling in patients with advanced breast cancer, according to the Stop&Go study presented at EBCC 2019.